Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | THRA | P10827 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8669256 | 0.86 | NPC1 (0.57) | ALDH1A1MEN1KMT2ALMNATHRB | |
| SCHEMBL13823608 | 0.86 | CYP2A6 (0.46) | ALDH1A1MEN1KMT2ALMNATHRB | |
| SCHEMBL5118727 | 0.82 | ALDH1A1 (0.50) | ALDH1A1MEN1KMT2ALMNATHRB | |
| SCHEMBL287047 | 0.79 | ALDH1A1 (0.41) | ALDH1A1MEN1KMT2ALMNATHRB | |
| SCHEMBL14278349 | 0.79 | NPC1 (0.53) | ALDH1A1KDM4ENPC1RAB9APOLB | |
| SCHEMBL24191934 | 0.78 | CYP2A6 (0.47) | ALDH1A1MEN1KMT2ALMNATHRB | |
| SCHEMBL19305874 | 0.78 | ALDH1A1 (0.60) | ALDH1A1MEN1KMT2ALMNATHRB | |
| SCHEMBL6627142 | 0.78 | ALDH1A1 (0.65) | ALDH1A1MEN1KMT2ALMNATHRB | |
| SCHEMBL5126551 | 0.76 | ALDH1A1 (0.41) | ALDH1A1MEN1KMT2ALMNATHRB | |
| SCHEMBL5126548 | 0.76 | ALDH1A1 (0.41) | ALDH1A1MEN1KMT2ALMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045546-A1 | Tetradydro-Naphthalene And Urea Derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-02-21 | — | — | US | disclosed |
| EP-1678123-A1 | TETRAHYDRO-NAPHTHALENE AND UREA DERIVATIVES | Bayer HealthCare AG (DE) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005040100-A1 | TETRAHYDRO-NAPHTHALENE AND UREA DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045546-A1 | Tetradydro-Naphthalene And Urea Derivatives | NMUR1, GPR17, NMUR2 | ALDH1A1 477/4885MEN1 3857/4885KMT2A 4656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.